News articles about Hospira (NYSE:HSP) have trended somewhat negative on Tuesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hospira earned a news impact score of 0.00 on Accern’s scale. Accern also gave press coverage about the healthcare company an impact score of 40.3598241623441 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Hospira (NYSE:HSP) remained flat at $$89.96 during trading on Tuesday. The stock has a market capitalization of $15,560.00 and a PE ratio of 37.64.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/2018/03/13/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-hospira-hsp-share-price/2025822.html.
Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.
Receive News & Ratings for Hospira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira and related companies with MarketBeat.com's FREE daily email newsletter.